Granada

Running trials

• Recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

  NCT07691970· Phase 3· Source

• Recruiting

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· Phase 3· Source

• Recruiting

  OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

  NCT06068049· Source

• Recruiting

  PICAROS - Acalabrutinib RWE on 1L CLL in Spain

  NCT05999877· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  AZAHAR Study To Describe Anifrolumab in a Real-World Setting

  NCT06626945· Source

• Completed

  Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.

  NCT06321731· Source

• Completed

  An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

  NCT05492877· Phase 2· Source

• Completed

  Tracking Treatment Pathways in Adult Patients With Hyperkalemia.

  NCT05408039· Source

• Completed

  Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

  NCT04676646· Phase 4· Source

• Completed

  Tezepelumab COPD Exacerbation Study

  NCT04039113· Phase 2· Source

• Completed

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· Phase 3· Source